Financial Performance - The annual revenue for the year was reported at $500 million, reflecting a 15% growth compared to the previous year[15]. - The company's operating revenue for 2022 was RMB 1,925.63 million, representing a year-on-year increase of 3.17%, primarily driven by revenue growth in Hong Kong, Macau, Taiwan, and overseas markets, with overseas revenue reaching RMB 807.27 million, up 21.25%[27]. - The net profit attributable to shareholders of the listed company was RMB 177.23 million, a decrease of 21.30% compared to the previous year, mainly due to changes in the fair value of financial assets and increased selling and administrative expenses[28]. - Basic and diluted earnings per share for 2022 were RMB 0.44, down 24.14% year-on-year, primarily due to reduced fair value gains and increased expenses[28]. - The net cash flow from operating activities was RMB 303.95 million, reflecting a 3.57% increase from the previous year[25]. - The company's total net assets attributable to shareholders at the end of 2022 were RMB 1,964.90 million, an increase of 9.65% compared to the end of 2021[25]. - The gross margin for the year improved to 60%, up from 55% in the previous year, due to operational efficiencies[14]. - The company reported a quarterly revenue of RMB 560.81 million in Q4 2022, showing a consistent upward trend throughout the year[30]. - The net profit attributable to shareholders in Q4 2022 was RMB 64.39 million, indicating a strong performance in the last quarter[31]. Research and Development - The company is investing $50 million in R&D for next-generation sequencing technologies, aiming to enhance accuracy and reduce costs by 20%[14]. - Research and development expenses accounted for 6.91% of operating revenue, a decrease of 1.15 percentage points from the previous year[27]. - The company has received 57 patents related to gene sequencing technology and 294 software copyrights, indicating its commitment to innovation[45]. - The company has developed a fully automated bioinformatics reporting machine and an automated library construction system, successfully completing the first generation of development[44]. - The company has established research cooperation with multiple top-tier hospitals for its independently developed pathogen metagenomic high-throughput detection products (mNGS) PD-seq series[84]. - The company has developed a comprehensive single-cell sequencing service capability, having published over 150 related research papers globally by the end of 2022[79]. - The company has achieved significant advancements in de novo sequencing technology, obtaining 4 invention patents and successfully assembling the T2T human genome sequence[72]. Market Expansion and Strategy - The company plans to expand its market presence in Europe, targeting a 30% increase in market share by 2025[16]. - The company aims to create a one-stop automated solution to support the implementation of NGS technology in hospitals[44]. - The company is actively expanding its clinical applications of gene technology, with its gene mutation detection kit being one of the first approved in China for high-throughput sequencing-based tumor gene detection[46]. - The company is focusing on integrating various omics data to provide unified management and analysis services for clients[40]. - The company aims to enhance its global localized service network and operational system by establishing new local laboratories worldwide, building on existing facilities in the US, Singapore, and the UK[165]. Corporate Governance - The board of directors has confirmed the authenticity, accuracy, and completeness of the annual report[4]. - The company has not disclosed any special arrangements for corporate governance[6]. - The company’s governance structure complies with relevant laws and regulations, with no significant discrepancies noted[174]. - The company’s financial status and major asset restructuring are supervised by the supervisory board to protect shareholder rights[175]. - The company’s board secretary is responsible for information disclosure and investor relations, ensuring timely and accurate information dissemination[174]. Risks and Challenges - The company has not reported any significant risks that could materially affect its operations during the reporting period[4]. - The company is facing risks from intense market competition leading to potential price declines in genomic services[103]. - The company is highly dependent on key suppliers like Illumina and Thermo Fisher, which poses a supply risk[104]. - The company plans to diversify its supplier base to mitigate reliance on a few key suppliers[104]. Innovations and Technology - The company has developed a targeted method for absolute quantification of amino acids, enhancing the stability and repeatability of the product[91]. - The company has optimized its RNA sequencing and epigenomics technologies, achieving a valid rate of over 70% in library construction for various species[76]. - The company has made significant breakthroughs in third-generation sequencing technology, achieving industry-leading results in metagenomic sequencing applications[83]. - The company is exploring new technologies such as long-read sequencing and methylation sequencing for clinical applications[84]. Shareholder Returns - The company plans to distribute a cash dividend of RMB 0.047 per share, totaling RMB 18,809,400, which represents 10.61% of the net profit attributable to shareholders[5]. - The company does not plan to issue bonus shares or convert capital reserves into share capital for the 2022 fiscal year[5]. - The company has a three-year dividend return plan for shareholders from 2022 to 2024, which was also approved by the board[191].

Financial Performance - The company's operating revenue for Q1 2023 was RMB 440,608,070.50, representing a year-on-year increase of 13.96%[15] - The net profit attributable to shareholders for the same period was RMB 22,501,126.20, reflecting a growth of 19.27% compared to the previous year[15] - The net profit attributable to shareholders after deducting non-recurring gains and losses increased by 60.88% due to higher sales revenue[23] - The basic and diluted earnings per share were both RMB 0.06, marking a 20.00% increase year-on-year[15] - The total operating revenue for Q1 2023 was CNY 440,608,070.50, representing an increase of 13.96% compared to CNY 386,628,023.16 in Q1 2022[33] - The net profit for Q1 2023 was CNY 24,422,331.28, compared to CNY 20,012,365.86 in Q1 2022, reflecting a growth of 22.99%[34] - The comprehensive income for Q1 2023 totaled CNY 20,232,967.10, an increase from CNY 16,743,883.58 in Q1 2022, marking a rise of 20.00%[34] - The basic earnings per share for Q1 2023 were CNY 0.06, compared to CNY 0.05 in Q1 2022, representing a 20% increase[34] Assets and Liabilities - The company's total assets at the end of the reporting period were RMB 3,080,178,634.03, up 1.05% from the end of the previous year[16] - The total equity attributable to shareholders was RMB 1,984,771,171.77, an increase of 1.01% compared to the previous year[16] - The total liabilities as of the reporting date were CNY 1,082,683,379.87, compared to CNY 1,072,569,721.30 from the previous period, indicating a slight increase of 0.10%[32] - The total equity increased to CNY 1,997,495,254.16 from CNY 1,975,704,645.51, reflecting a growth of 1.10%[32] - Total current assets amounted to CNY 2,082,047,389.48, slightly increasing from CNY 2,018,065,556.96, an increase of about 3.2%[53] - Non-current assets totaled approximately 998.13 million, a decrease from 1,030.21 million[54] Cash Flow - The net cash flow from operating activities was negative at RMB -25,314,401.68, with increased employee compensation and VAT payments contributing to this[24] - Cash inflow from operating activities totaled CNY 412,424,974.15, an increase from CNY 349,751,610.39 in the previous period, representing an increase of approximately 17.9%[36] - Cash outflow from operating activities decreased to CNY 437,739,375.83 from CNY 535,891,915.49, a reduction of about 18.3%[36] - Net cash flow from operating activities improved to -CNY 25,314,401.68 from -CNY 186,140,305.10, indicating a significant reduction in losses[36] - Cash inflow from investment activities was CNY 376,954,964.41, down from CNY 915,741,224.59, a decrease of approximately 58.8%[36] - Cash outflow from investment activities decreased to CNY 889,497,929.61 from CNY 960,077,947.82, a reduction of about 7.4%[36] - Net cash flow from investment activities was -CNY 512,542,965.20, worsening from -CNY 44,336,723.23[36] - Cash inflow from financing activities was CNY 22,450,000.00, down from CNY 52,000,000.00, a decrease of approximately 56.8%[37] - Cash outflow from financing activities decreased to CNY 6,885,657.76 from CNY 56,286,973.22, a reduction of about 87.8%[37] - The ending cash and cash equivalents balance was CNY 301,595,998.13, down from CNY 650,153,286.67, a decrease of approximately 53.7%[37] Expenses - Research and development expenses totaled RMB 22,660,069.00, which is a decrease of 11.31% year-on-year, accounting for 5.14% of operating revenue[16] - The research and development expenses for Q1 2023 were CNY 22,660,069.00, slightly up from CNY 21,864,425.24 in Q1 2022, showing an increase of 3.64%[33] - The financial expenses decreased significantly to CNY 1,133,681.58 in Q1 2023 from CNY 2,407,645.87 in Q1 2022, a reduction of 53.15%[33] - The company reported a decrease in tax expenses to CNY 4,813,280.93 in Q1 2023 from CNY 2,242,155.78 in Q1 2022, indicating a significant increase in profitability[33] Shareholder Information - The total number of common shareholders at the end of the reporting period was 5,044[25] - Accounts payable increased to approximately 187.82 million from 131.65 million, reflecting a growth of about 42.6%[54] - Contract liabilities decreased to approximately 696.94 million from 723.99 million, a decline of about 3.8%[54] - Employee compensation payable decreased to approximately 50.11 million from 61.69 million, a reduction of about 18.7%[54] - Tax payable decreased to approximately 59.92 million from 81.48 million, a decline of about 26.5%[54] - Other payables decreased to approximately 8.66 million from 9.63 million, a reduction of about 10.1%[54] Strategic Outlook - The company is focusing on expanding its market presence and enhancing product development strategies[55] - Future outlook includes potential mergers and acquisitions to strengthen market position[55] - The company plans to invest in new technologies to drive growth and innovation[55]

本公司董事会及全体董事保证本公告内容不存在任何虚假记载、误导性陈述 或者重大遗漏，并对其内容的真实性、准确性和完整性依法承担法律责任。 证券代码：688315 证券简称：诺禾致源 公告编号：2023-017 北京诺禾致源科技股份有限公司 关于召开 2022 年度业绩说明会的公告 重要内容提示： 会议召开时间：2023 年 4 月 20 日(星期四)下午 13:00-14:00 会 议 召 开 地 点 ： 上 海 证 券 交 易 所 上 证 路 演 中 心 （ 网 址 ： http://roadshow.sseinfo.com/） 会议召开方式：上证路演中心网络互动 投资者可于 2023 年 4 月 13 日(星期四)至 4 月 19 日(星期三)16:00 前登录上 证路演中心网站首页点击"提问预征集"栏目或通过公司邮箱ir@novogene.com进 行提问。公司将在说明会上对投资者普遍关注的问题进行回答。 北京诺禾致源科技股份有限公司（以下简称"公司"）已于 2023 年 4 月 13 日 发布公司 2022 年年度报告，为便于广大投资者更全面深入地了解公司 2022 年度 经营成果、财务状况，公司计划于 ...

Financial Performance - Revenue for Q3 2022 reached ¥515,103,215.31, an increase of 8.61% year-over-year[8] - Net profit attributable to shareholders was ¥56,142,907.27, up 18.25% compared to the same period last year[8] - Net profit excluding non-recurring gains and losses increased by 43.90% to ¥57,433,960.16 in Q3 2022[8] - Basic earnings per share for Q3 2022 was ¥0.14, a decrease of 17.65% year-to-date[12] - Total operating revenue for the first three quarters of 2022 reached ¥1,364,823,824.09, an increase of 6.93% compared to ¥1,275,995,770.26 in the same period of 2021[33] - Net profit for the third quarter of 2022 was ¥115,306,030.16, a decrease of 12.04% from ¥131,029,348.76 in the same quarter of 2021[36] - Earnings per share for the third quarter of 2022 were ¥0.28, down from ¥0.34 in the same quarter of 2021[41] - Other comprehensive income after tax for the third quarter of 2022 was ¥15,829,461.82, compared to -¥5,473,124.39 in the same quarter of 2021[39] Assets and Liabilities - Total assets at the end of Q3 2022 amounted to ¥2,907,610,117.99, reflecting a 1.69% increase from the end of the previous year[12] - The company's total liabilities amounted to ¥991,630,752.17, a decrease from ¥1,061,852,902.16 in the previous year[33] - Total liabilities decreased to CNY 585,684,353.65 in Q3 2022 from CNY 654,114,652.91 in Q3 2021, a reduction of approximately 10.5%[57] - The total assets of the company reached ¥2,907,610,117.99, an increase from ¥2,859,351,915.80 in the previous year[33] - The total cash and cash equivalents at the end of the period were 11,400,109.94 RMB, down from 18,554,214.61 RMB in the previous year, reflecting a decrease of 38.5%[66] Cash Flow - Cash flow from operating activities for the year-to-date was ¥61,347,057.32, attributed to increased customer payments and VAT refunds[15] - The net cash flow from operating activities for the first three quarters of 2022 was ¥61,347,057.32, a significant improvement compared to a net outflow of ¥42,937,286.65 in the same period of 2021[43] - Cash inflow from operating activities totaled ¥1,455,840,121.68, up from ¥1,176,218,057.77 in the previous year, representing an increase of approximately 23.7%[43] - The total cash outflow from operating activities was ¥1,394,493,064.36, compared to ¥1,219,155,344.42 in 2021, indicating a rise of about 14.4%[43] - The net cash flow from financing activities was -¥40,300,244.68, a decline from a positive cash flow of ¥404,601,483.16 in the same period of 2021[47] Research and Development - R&D investment for Q3 2022 was ¥39,476,673.48, a decrease of 12.05% year-over-year[12] - R&D expenditure accounted for 7.66% of revenue, down 1.85 percentage points from the previous year[12] - Research and development expenses for the first three quarters of 2022 were ¥87,826,057.16, compared to ¥95,349,213.00 in the same period of 2021, indicating a decrease of 7.93%[36] - Research and development expenses for the first three quarters of 2022 amounted to CNY 52,809,206.07, down 29.1% from CNY 74,431,940.12 in the same period of 2021[57] Shareholder Information - The total number of ordinary shareholders at the end of the reporting period was 4,976[18] - There were no significant changes in the top ten shareholders or their holdings during the reporting period[24] - The total equity attributable to shareholders increased to ¥1,907,437,664.01 from ¥1,791,810,149.25, representing a growth of 6.47%[33] - The company's total equity increased to CNY 1,686,224,176.68 in Q3 2022 from CNY 1,654,836,428.74 in Q3 2021, representing a growth of about 1.9%[56] Future Outlook - The company has not disclosed any significant new product developments or market expansions during the reporting period[25] - The company plans to focus on market expansion and new product development in the upcoming quarters to drive growth[60]

Financial Performance - The company reported a total revenue of RMB 500 million for the first half of 2022, representing a year-on-year increase of 25%[2]. - The company reported a significant increase in revenue, achieving a total of 1.2 billion RMB for the first half of 2022, representing a 25% year-over-year growth[21]. - The company's operating revenue for the first half of the year reached ¥849,720,608.78, an increase of 5.99% compared to the same period last year[30]. - Net profit attributable to shareholders decreased by 30.50% to ¥56,696,573.09, primarily due to reduced input VAT credits and increased sales and management expenses[30]. - The basic and diluted earnings per share were both ¥0.14, down 36.36% year-on-year, influenced by decreased other income and increased expenses[30]. - The net cash flow from operating activities was -¥19,075,287.48, an improvement from -¥111,111,060.98 in the previous year, mainly due to increased customer payments and tax refunds[30]. - The company's cash and cash equivalents decreased by 32.64% to RMB 604,830,842.10, down from RMB 897,844,459.92 at the end of the previous year[97]. - The company achieved operating revenue of 849.72 million yuan, a year-on-year increase of 5.99%[80]. - The cost of goods sold was RMB 490,975,213.17, reflecting a slight increase of 1.00% from RMB 486,110,561.37 year-on-year[92]. - Sales expenses rose significantly by 26.20% to RMB 158,139,247.54, up from RMB 125,310,449.03, primarily due to increased personnel compensation and marketing expenses[92]. - Management expenses increased by 41.00% to RMB 89,992,628.52, compared to RMB 63,826,789.60 in the previous year, driven by higher salaries and consulting fees[92]. User Growth and Market Expansion - User data showed an increase in active users by 15%, reaching a total of 1.2 million users by the end of June 2022[2]. - User data showed a 30% increase in active users, reaching 500,000 by the end of the reporting period[21]. - The company expects a revenue growth of 30% for the second half of 2022, driven by new product launches and market expansion strategies[2]. - Market expansion plans include entering three new international markets by Q4 2022, aiming for a 10% market share in each[21]. - The company plans to expand its market presence in Southeast Asia, targeting a 10% market share by the end of 2023[2]. Research and Development - Investment in R&D increased by 20% compared to the previous year, focusing on innovative technologies in genetic testing[2]. - The company is investing heavily in R&D, with a budget increase of 15% compared to the previous year, focusing on genomic technologies[21]. - The R&D expenditure accounted for 6.58% of operating revenue, a slight decrease of 0.02 percentage points compared to the same period last year[30]. - The company’s R&D investment reached CNY 55.88 million, a year-on-year increase of 5.61%, with R&D expenses accounting for 6.58% of revenue, a slight decrease of 0.02 percentage points[56]. - The company has developed 45 patents related to gene sequencing technology and 274 software copyrights, covering various research areas including molecular mechanisms of diseases and genetic diversity[39]. - The company has developed a series of technical reserves in complex sequencing technologies, including transcriptomics and regulatory genomics, to expand the application scenarios of new technologies[53]. Product Development and Innovation - The company has launched a new product line that is projected to contribute an additional RMB 100 million in revenue by the end of 2022[2]. - New product launches are expected to contribute an additional 200 million RMB in revenue by the end of the year[21]. - The company has developed innovative tumor gene mutation detection kits, becoming one of the first high-throughput tumor gene detection kit manufacturers approved for market in China[56]. - The company has introduced a rapid molecular POCT platform for respiratory pathogen detection, including a novel coronavirus nucleic acid detection kit, which has received EU CE certification[56]. - The company has developed a fully automated production system, enhancing measurement efficiency and stability while reducing costs[50]. Strategic Acquisitions and Partnerships - A strategic acquisition of a local biotech firm is in progress, expected to enhance the company's capabilities in personalized medicine[2]. - The company is exploring potential acquisitions to enhance its technology portfolio, with a target of completing at least one acquisition by the end of 2022[21]. - A new strategic partnership was announced, expected to enhance distribution channels and increase market penetration by 25%[21]. Risk Management and Compliance - The company has identified potential risks related to regulatory changes, which may impact future operations and market strategies[2]. - The company is actively monitoring regulatory changes in the genomics testing industry to ensure compliance and avoid penalties[89]. - The company recognizes the risk of talent shortages as it expands, and is focused on optimizing personnel structure and attracting skilled professionals[89]. - The ongoing global pandemic poses a risk to the company's performance, prompting a push towards digital operations and automation to maintain competitiveness[89]. Environmental and Social Responsibility - The company has implemented measures to reduce carbon emissions, including energy-saving actions and promoting a green office culture[127]. - The company has taken steps to manage waste, including proper disposal of hazardous waste and promoting recycling initiatives[129]. - The company has not reported any environmental violations or issues that would affect its operations[126]. Shareholder Commitments and Governance - The company has committed to long-term promises regarding competition and related transactions, with strict adherence to these commitments[134]. - The company guarantees that all commitments made are true, accurate, and complete, accepting legal responsibility for any misrepresentation[148]. - The company will ensure compliance with the rules set by the China Securities Regulatory Commission regarding share transfer restrictions[154]. - The company will publicly apologize and rectify any breaches of commitments made by its shareholders or executives[148].

Financial Performance - The company's operating revenue for Q1 2022 was ¥386,628,023.16, representing a year-on-year increase of 5.83%[6] - The net profit attributable to shareholders of the listed company was ¥18,866,423.65, a decrease of 42.66% compared to the same period last year[6] - The net profit attributable to shareholders after deducting non-recurring gains and losses was ¥12,381,188.53, reflecting a slight increase of 2.30% year-on-year[6] - Basic and diluted earnings per share were both ¥0.05, down 44.44% year-on-year[9] - Net profit for Q1 2022 was CNY 20,012,365.86, a decrease of 40.8% from CNY 33,619,210.00 in Q1 2021[39] - Operating profit for Q1 2022 was CNY 22,255,507.84, down 41.5% from CNY 37,916,476.22 in Q1 2021[37] - Total comprehensive income for Q1 2022 was CNY 16,743,883.58, down from CNY 35,621,664.65 in Q1 2021[39] Cash Flow - The net cash flow from operating activities was -¥186,140,305.10, indicating a significant cash outflow[9] - Cash flow from operating activities for Q1 2022 was negative CNY 186,140,305.10, compared to negative CNY 139,732,903.79 in Q1 2021[44] - The net cash flow from investing activities was -$44.34 million, a decrease from $80.12 million in the previous period[46] - Cash inflow from financing activities totaled $52 million, compared to $12 million in the prior period[46] - The net cash flow from financing activities was -$4.29 million, a significant improvement from -$42.87 million previously[46] - The net decrease in cash and cash equivalents was -$240.82 million, worsening from -$103.28 million in the previous period[46] - The ending balance of cash and cash equivalents was $650.15 million, down from $890.98 million at the beginning of the period[46] Assets and Liabilities - Total assets at the end of the reporting period were ¥2,747,597,284.93, a decrease of 3.91% from the end of the previous year[9] - Current assets totaled approximately ¥1.74 trillion, down from ¥1.91 trillion, indicating a decrease of around 8.9%[32] - Cash and cash equivalents were reported at ¥651.55 million, a significant drop from ¥897.84 million, representing a decline of approximately 27.4%[29] - Accounts receivable increased to ¥578.95 million from ¥527.59 million, marking an increase of about 9.7%[29] - Total liabilities were approximately ¥929.57 million, down from ¥1.06 billion, reflecting a decrease of about 12.4%[34] - Shareholders' equity totaled approximately ¥1.82 billion, an increase from ¥1.80 billion, indicating a growth of about 1.4%[34] Research and Development - Research and development expenses totaled ¥25,549,842.88, which is 6.61% of operating revenue, down by 1.04 percentage points year-on-year[9] - Research and development expenses for Q1 2022 were CNY 21,864,425.24, a decrease of 22% from CNY 27,956,011.94 in Q1 2021[37] Shareholder Information - The total number of ordinary shareholders at the end of the reporting period was 6,256[17] - The company reported a total of ¥6,485,235.12 in non-recurring gains and losses for the period[10]

Financial Performance - The company achieved operating revenue of RMB 1,866,396,324.39, representing a year-on-year growth of 25.26%[130]. - Net profit attributable to shareholders reached RMB 22,498,610, representing a significant increase of 515.74% year-on-year[130]. - The net profit attributable to shareholders after deducting non-recurring gains and losses was RMB 17,560,390, reflecting a remarkable growth of 696.11%[130]. - The company's total assets reached CNY 285,935,190, marking a year-on-year growth of 41.22%[130]. - The net assets attributable to shareholders increased to CNY 179,181,010, a growth of 60.52% year-on-year[130]. - The net cash flow from operating activities was CNY 29,347,370, showing a decrease of 14.21% compared to the previous year[130]. - The company plans to distribute a cash dividend of RMB 0.06 per share, totaling RMB 24,012,000, which represents 10.67% of the net profit attributable to shareholders[7]. - The company's operating revenue for 2021 was CNY 1,866,396,324.39, representing a year-on-year increase of 25.26%[38]. - The net profit attributable to shareholders for 2021 was CNY 224,986,098.35, a significant increase of 515.74% compared to the previous year[38]. - The net profit attributable to shareholders after deducting non-recurring gains and losses was CNY 175,603,907.22, up 696.11% year-on-year[38]. Research and Development - The company is investing RMB 200 million in R&D for new technologies, focusing on genomic sequencing advancements[21]. - Research and development investment totaled RMB 150.41 million, reflecting a year-on-year increase of 33.91%[48]. - The R&D expenditure as a percentage of operating revenue was 8.06%, up from 7.54% in the previous year[38]. - The number of R&D personnel increased to 443, accounting for 20.42% of the total workforce, reflecting a focus on innovation[113]. - The company is developing a new product for transcription regulation and 3D genome analysis, with an expected total investment of CNY 87.90 million[96]. - The company is working on an automated bioinformatics workflow project to improve project delivery efficiency and reduce human error[96]. - The company aims to optimize the cost of second-generation sequencing sample preparation and library construction through high-performance automation[96]. - The company has developed a targeted gene detection kit for lung cancer, which has received regulatory approval for three medical device categories, focusing on genes such as EGFR, ALK, and KRAS[7]. Market Expansion and Strategy - The company provided guidance for the next quarter, expecting revenue to be between RMB 1.6 billion and RMB 1.8 billion, indicating a growth rate of 20% to 30%[21]. - Market expansion plans include entering three new international markets by the end of the fiscal year, targeting a 10% increase in overall market share[21]. - The company is actively expanding its product line into IVD, genetics, and pathogen detection, aiming to mitigate risks associated with a single service offering[120]. - The company plans to deepen its global business layout by establishing localized laboratories and enhancing its service network, with a goal to increase its international brand recognition and market penetration[184]. - The company is targeting the clinical testing market, which is still in its early stages, by leveraging its proprietary gene mutation detection kits and expanding its product offerings[184]. Compliance and Governance - The company has received a standard unqualified audit report from its accounting firm[6]. - The board of directors has confirmed the accuracy and completeness of the annual report[4]. - The company has not reported any significant risks that could materially affect its operations during the reporting period[5]. - The company has not faced any violations of decision-making procedures regarding external guarantees[10]. - The company has not reported any special arrangements for corporate governance[8]. - The company emphasizes the importance of risk awareness regarding forward-looking statements in the report[9]. - The company adheres to strict governance practices, ensuring compliance with relevant laws and regulations while maintaining transparency in its operations[190]. - The company’s governance structure meets the requirements set by the China Securities Regulatory Commission, ensuring the protection of shareholder rights and interests[193]. Innovation and Technology - The company has established a leading gene sequencing platform with high-throughput sequencing technology and bioinformatics analysis, providing multi-level research services and solutions for life sciences and clinical applications[52]. - The company has developed over 10 personalized targeted metabolomics methods and projects, and launched 4D proteomics products to meet diverse customer needs in proteomics[51]. - The company has successfully automated the pre-treatment production line for mass spectrometry, expanding automation applications to multi-omics business areas, enhancing efficiency and capacity[51]. - The company has developed a comprehensive multi-omics integration research technology platform, expanding its capabilities in proteomics and metabolomics, with targeted metabolomics achieving high sensitivity and accuracy[86]. - The company has launched an online information collection system to improve operational efficiency and establish a comprehensive global information management matrix[51]. - The company has achieved a DNA extraction success rate of 93.28%, RNA extraction success rate of 88.97%, and microbial extraction amplification success rate of 98.58%[81]. - The company has developed innovative tumor gene detection medical devices based on core gene sequencing technology, actively expanding into multiple sectors including IVD, genetics, and pathogens[78]. Customer and Market Insights - User data showed a 30% increase in active users, reaching 2 million by the end of the quarter[21]. - The company has established a global technical service network, covering approximately 70 countries and regions, and serving over 5,900 clients, including top research institutions[54]. - The company primarily serves research institutions, hospitals, and pharmaceutical companies, utilizing a direct sales model to engage clients[60]. - The company has established a stable long-term partnership with qualified suppliers, ensuring product quality and supply capabilities[58]. - The company has a global market presence, serving over 5,900 clients across approximately 70 countries, with significant contributions from overseas technology service business[114]. Risks and Challenges - The company faces risks related to product and service singularity, as it currently lacks clinical application qualifications in certain areas, which could impact its competitive edge[120]. - The company acknowledges the risk of intense market competition leading to potential price declines, and it plans to enhance service quality and operational efficiency to maintain competitiveness[121]. - The company is increasing supplier diversity to reduce reliance on major suppliers like Illumina and Thermo Fisher, addressing supply chain risks[121]. - The company is expanding its overseas operations while ensuring compliance with local laws and regulations to mitigate operational risks in international markets[121].

Financial Performance - The company's operating revenue for Q3 2021 was ¥474,266,282.44, representing a year-over-year increase of 28.48%[7] - The net profit attributable to shareholders for Q3 2021 was ¥47,478,898.42, reflecting a significant increase of 105.75% compared to the same period last year[7] - The net profit attributable to shareholders after deducting non-recurring gains and losses for Q3 2021 was ¥39,912,560.35, up 94.18% year-over-year[7] - Total operating revenue for the first three quarters of 2021 reached ¥1,275,995,770.26, a 33.7% increase from ¥954,285,378.45 in the same period of 2020[34] - Net profit for the third quarter of 2021 was ¥131,029,348.76, a significant recovery from a net loss of ¥55,564,509.15 in the same quarter of 2020[34] - The total comprehensive income for the third quarter of 2021 was ¥125,556,224.37, compared to a loss of ¥56,533,496.23 in the same quarter of 2020[34] - Basic and diluted earnings per share for the first three quarters of 2021 were CNY 0.34, compared to a loss of CNY 0.15 in the same period of 2020[40] Research and Development - Research and development (R&D) expenses totaled ¥45,116,002.74 for Q3 2021, an increase of 65.25% compared to the same period last year[11] - R&D expenses accounted for 9.51% of operating revenue in Q3 2021, an increase of 2.11 percentage points year-over-year[11] - Research and development expenses for the third quarter of 2021 were ¥95,349,213.00, up from ¥78,702,531.64 in the same quarter of 2020, indicating a 21.1% increase[34] - The company is focused on expanding its market presence and enhancing its product offerings through ongoing research and development initiatives[30] Assets and Liabilities - Total assets at the end of Q3 2021 were ¥2,523,474,560.67, a 24.63% increase from the end of the previous year[11] - The company's total assets reached ¥2,523,474,560.67, up from ¥2,024,732,082.96 in the previous year[34] - Accounts receivable increased significantly to RMB 433,697,035.44 from RMB 321,999,155.20, reflecting a growth of approximately 34.7% year-over-year[26] - The company's inventory also saw an increase, rising to RMB 260,309,304.39 from RMB 201,581,129.33, which is a growth of around 29.1%[26] - Total current liabilities decreased to RMB 779,352,409.10 from RMB 897,478,042.40, showing a reduction of approximately 13.2%[29] - The company's total liabilities amounted to ¥815,302,474.89, down from ¥903,855,566.28 in the previous year[34] - The company's long-term equity investments remained stable at RMB 23,333,615.04, unchanged from the previous year[29] - The company’s total liabilities decreased, indicating improved financial health and stability[29] Cash Flow - The company reported a net cash flow from operating activities of -¥42,937,286.65 for the year-to-date period[11] - Cash inflow from operating activities totaled CNY 1,176,218,057.77, an increase from CNY 1,089,193,214.42 year-over-year[40] - Net cash outflow from operating activities was CNY -42,937,286.65, slightly worse than CNY -41,235,843.06 in the previous year[40] - Cash inflow from investment activities was CNY 827,809,806.35, up from CNY 473,712,687.54 in the same period last year[42] - Net cash outflow from investment activities was CNY -291,235,754.49, compared to a net inflow of CNY 40,292,203.88 in the previous year[42] - Cash inflow from financing activities was CNY 488,781,961.60, compared to CNY 276,118,796.66 in the same period last year[42] - Net cash inflow from financing activities was CNY 404,601,483.16, significantly higher than CNY 9,208,013.77 in the previous year[42] - The ending cash and cash equivalents balance was CNY 510,342,781.55, up from CNY 315,972,017.86 at the end of the previous year[42] Equity - Shareholders' equity attributable to the parent company reached ¥1,702,185,386.64, up 52.49% compared to the previous year[11] - The equity attributable to shareholders of the parent company increased to ¥1,702,185,386.64 from ¥1,116,250,391.49, marking a 52.4% growth[34] - Total equity remained stable at 1,120,876,516.68, unchanged from the previous period[51]

证券代码：688315 证券简称：诺禾致源 公告编号：2021-031 北京诺禾致源科技股份有限公司 关于参加北京辖区上市公司投资者集体接待日的公告 本公司董事会及全体董事保证本公告内容不存在任何虚假记载、误导性陈 述或者重大遗漏，并对其内容的真实性、准确性和完整性依法承担法律责任。 为进一步加强与广大投资者的沟通交流，北京诺禾致源科技股份有限公司（以 下简称"公司"）将参加"2021 年北京辖区上市公司投资者集体接待日"活动，现 将有关事项公告如下： 本次集体接待日活动将采取网络远程的方式举行，投资者可以登录"上证路 演中心"网站（http://roadshow.sseinfo.com）或关注微信公众号上证路演中心， 参与本次投资者集体接待日活动，活动时间为 2021 年 9 月 23 日（星期四）15:00 至 17:00。 届时公司的董事会秘书王其锋和财务总监施加山将通过网络在线交流形式与 投资者就公司治理、发展战略、经营状况、股权激励和可持续发展等投资者关注 的问题进行沟通。 欢迎广大投资者积极参与。 特此公告。 北京诺禾致源科技股份有限公司董事会 2021 年 9 月 11 日 1 ...

Financial Performance - The company reported a revenue of 1.2 billion RMB for the first half of 2021, representing a year-over-year growth of 30%[1]. - The company expects a revenue guidance of 2.5 billion RMB for the full year 2021, indicating a growth target of 20%[1]. - The company reported a revenue of RMB 300 million for the first half of 2021, representing a year-on-year increase of 25%[20]. - The company's operating revenue for the first half of 2021 was RMB 801.73 million, representing a 37.02% increase compared to RMB 585.14 million in the same period last year[32]. - Net profit attributable to shareholders was RMB 81.58 million, a significant recovery from a loss of RMB 75.32 million in the previous year[32]. - The company achieved a revenue of approximately ¥415.21 million, with a net profit of around ¥307.38 million, reflecting a strong performance in the first half of 2021[94]. - The company reported a significant increase in revenue, achieving a total of 1.5 billion in the first half of 2021, representing a year-over-year growth of 25%[174]. User Growth - User data indicates an increase in active users by 25% compared to the same period last year, reaching 500,000 active users[1]. - User data showed a growth in active users by 15% compared to the previous year, reaching a total of 1.5 million active users[20]. - User data showed a total of 10 million active users, an increase of 15% compared to the previous year[174]. Research and Development - Research and development expenses increased by 10% to 150 million RMB, focusing on innovative genomic technologies[1]. - Investment in R&D increased by 30% year-on-year, focusing on the development of new technologies and products in the genomic testing sector[20]. - The total R&D investment for the period reached ¥52,912,343.77, an increase of 2.94% compared to the previous period[73]. - The company’s R&D expenses for the current period were ¥51,604,661.95, a slight increase of 0.40% from the previous period[73]. - The company has obtained 37 patents related to gene sequencing technology and 225 software copyrights, demonstrating its strong innovation capabilities[40]. - The company has developed a standardized transcriptome and regulatory group data analysis method, shortening delivery times and expanding application ranges[60]. Market Expansion - The company is expanding its market presence in Southeast Asia, targeting a 15% market share by the end of 2022[1]. - The company plans to expand its market presence in Southeast Asia, targeting a 10% market share by the end of 2022[20]. - Market expansion plans include entering three new international markets by Q3 2021, aiming for a 10% market share in each[174]. Product Development - New product launches include a next-generation sequencing platform expected to enhance processing speed by 40%[1]. - A new product line is set to launch in Q3 2021, anticipated to contribute an additional RMB 50 million in revenue[20]. - The company is developing a high-throughput newborn genetic disease screening product based on the Illumina sequencing platform, covering over 900 genes and significantly improving screening efficiency[5]. - The company has launched innovative tumor gene mutation detection kits, approved as innovative medical devices by NMPA[65]. Financial Health - The company's total assets increased by 22.06% to RMB 2.47 billion from RMB 2.02 billion at the end of the previous year[32]. - The net assets attributable to shareholders rose by 47.36% to RMB 1.64 billion compared to RMB 1.12 billion at the end of the previous year[32]. - The company reported a net cash flow from operating activities of RMB -111.11 million, an improvement from RMB -181.87 million in the previous year[32]. - The company achieved operating revenue of ¥801,729,487.82, representing a year-on-year growth of 37.02%[105]. Strategic Initiatives - A strategic acquisition of a local biotech firm is expected to enhance the company's capabilities in genetic testing, with a projected completion date in Q4 2021[20]. - The company is exploring partnerships with international research institutions to enhance its product offerings and technological advancements[20]. - The company has initiated a sustainability strategy aimed at reducing operational costs by 15% over the next two years[20]. Governance and Compliance - The board of directors has confirmed the accuracy and completeness of the financial report, ensuring transparency[1]. - The company has not proposed any profit distribution or capital reserve transfer plans for this reporting period[1]. - The company is committed to improving its internal control systems and talent management strategies to address risks related to core technology leakage and personnel turnover[112]. Risk Management - The company faces significant risks in technology development, particularly in the genomic application industry, where failure to develop commercially viable products could adversely affect profitability[110]. - The company is heavily reliant on key suppliers, Illumina and Thermo Fisher, for sequencing instruments and reagents, which poses a risk due to limited supplier diversity[112]. - The company acknowledges the potential impact of ongoing COVID-19 pandemic fluctuations on future performance and is enhancing digital operations to maintain competitiveness[116].